

# **Clinical statistical analysis with comparison between pelvic and non-pelvic chondrosarcoma**

Sayed Abdulla Jami<sup>1</sup>, Shi Jiandang<sup>1\*</sup>, Brotendu Shekhar Roy<sup>2</sup>, Zhanwen Zhou<sup>1</sup> and  
Liu Chang Hao<sup>1</sup>

<sup>1</sup>Department of Spinal Surgery, General Hospital of Ningxia Medical University, Ningxia Medical University 804 Shengli Street, Xingqing District, Yinchuan, 750004, Ningxia, People's Republic of China.

<sup>2</sup>1<sup>st</sup> affiliated hospital of Nanchang University, No.17 Yong Wai Zheng Street Donghu District, Nanchang, 330006, Jiangxi, People's Republic of China.

Received: 29 February 2020

Accepted: 11 September 2020

*\*Corresponding author: shi\_jiandang@outlook.com*

**DOI 10.5001/omj.2021.65**

## **Abstract**

### **Background**

Chondrosarcomas are a rare tumor that has a variable biological characteristic. Also, their treatment clinically and surgically is controversial. Analyze the clinical statistics and prognostic factors of pelvic chondrosarcoma to provide a reference for clinical diagnosis and treatment.

### **Method**

A total of 73 cases of chondrosarcoma were collected, including 24 pelvic from 2008 to 2017 hospital database and divided into 2 groups of pelvic chondrosarcoma and non-pelvic chondrosarcoma. The clinical characteristics and prognostic factors of pelvic chondrosarcoma were analyzed by different statistic methods.

### **Result**

Among the 24 pelvic chondrosarcoma patients, the ratio of male to female was 1.4:1, and the median age was 43.5 years. According to the classification proposed by Enneking, there were 5 in

area I, 14 in area II, and 5 in area III; Histological grading of chondrosarcoma grade I in 1 case, II in 15 cases, III in 8 cases; The histological type was 17 conventional, 3 dedifferentiated, 2 secondary, myxoid 1 and mesenchymal 1. The overall survival rates were 3, 5 and 10 years ( $82.2\pm 8.1$ ) %, ( $77.3\pm 8.9$ ) %, ( $52.4\pm 12.1$ ) % respectively. The local recurrence rate of pelvic chondrosarcoma after surgical resection (83.3%) was significantly higher than that of other sites (34.7%), and the difference was statistically significant ( $P=0.000$ ); The final proportion of amputation rate (50.0%) was also higher than other parts (20.4%) with a statistically significant difference ( $P=0.000$ ). But the total survival of the 2 groups is ( $P=0.216$ ).

### **Conclusion**

Chondrosarcoma of bone generally has an excellent prognosis when optimal diagnosed and treated by an experienced team of specialists. But pelvic chondrosarcoma has a higher local recurrence rate than the other sites and is tend to result in amputation. Early local recurrence after surgery indicates a poor prognosis.

**Keywords** pelvic chondrosarcoma; prognostic factors; tumor recurrence.

### **Introduction**

Chondrosarcoma is a malignant tumor of cartilage origin, and its incidence rate is second in among primary malignant bone tumors [1]. It can be divided into different histological types according to histological characteristics and pathological sites. Besides, the tumors have considerable variation in outcome depending on size, histologic grade, Musculoskeletal Tumor Society (MSTS) stage, and tumor type. According to the incidence rate grading from a higher rate to lower rate follows: the common central type, conventional, dedifferentiated type, mesenchymal, myxoid type, clear cell type [1-2] are proposed. The tumor grade and the anatomic site are important because both influence the type of treatment and outcome. Chondrosarcoma responds poorly to traditional chemotherapy and radiotherapy. Whether responding to conventional adjuvant therapy for a higher-lower grade or advanced chondrosarcoma is still controversial [3-6]. Surgical treatment is the only known treatment with definite results at present. The pelvis is the second most common site of chondrosarcoma [7-8]. Due to the complicated and special anatomical structure, it's difficult for resection and reconstruction of the site, the intraoperative bleeding is high, and the incidence of surgical complications is high, so Its clinical treatment is always challenging[9]. In this study,

medical records of 24 patients with pelvic chondrosarcoma were retrospectively analyzed. Also, summarize the clinical statistics evidence of pelvic chondrosarcoma and analyze its prognostic factors.

## Materials and methods

### General information

A total of 78 cases of chondrosarcoma were confirmed by pathological examination and admitted to General Hospital from 2008 to 2017 according to the hospital medical record database. Five cases were not included in the study due to a lack of data. Out of the 73 included patients, 24 were pelvic chondrosarcomas; 14 males and 10 females with a ratio of 1.4:1. The patients were aged from 22 to 69 years, with a median age of 43.5 years. Pelvic tumors were partitioned according to the Enneking system [10], located 5 cases in area I, 14 cases in area II, 5 cases in area III. All patients were accepted puncture or incision biopsy. Histological grading of chondrosarcoma I grade 1 case, II grade 15 cases, 8 cases in III grade; The histological type was normal central type in 17 cases, dedifferentiated type in 3 cases, secondary type in 2 cases, myxoid type and mesenchymal type each 1 case. To better understanding all subtype of chondrosarcoma, the author collected all data and summarized in **Table 1**.

**Table 1-** Overview of clinical characteristics and therapeutic options in all subtypes of chondrosarcoma of bone:

|                            | Conventional primary central chondrosarcoma                  | Conventional secondary peripheral chondrosarcoma | Dedifferentiated chondrosarcoma   | Mesenchymal chondrosarcoma  | Clear cell chondrosarcoma               |
|----------------------------|--|--|-----------------------------------|---|---|
| % of all chondrosarcoma    | ~75%   | ~10%   | ~10%                              | <2%   | <2%                                     |
| Precursor lesion           | Enchondroma (up to 40%?)                                     | Osteochondroma (100%)                            | Conventional chondrosarcoma       | None  | None                                    |
| Occurrence within syndrome | Enchondromatosis (Ollier disease)                            | Multiple osteochondromas (MOs)                   | Rarely in MOs or enchondromatosis | None  | None                                    |
| Age                        | >50 years  | Younger than central chondrosarcoma              | Median age 59 years               | Any age (peak in second and third decade)   | Any age (peak in third to fifth decade) |
| Preferential location      | Pelvis, proximal femur, proximal humerus, distal femur, ribs | Pelvis, shoulder girdle bones                    | Femur and pelvis                  | 65%–86% skeleton (jawbones, ribs, ilium, vertebrae)<br>14%–43% Extra-osseous (meninges) | Epiphysis of humeral or femoral head    |
| Histological grading       | Grade I–III  | High grade                                       | High grade                        | Low grade   |   |
| Survival                   | Grade I, 83%; grade II, 64%; grade III, 29% at               | 24% at 5 years                                   | 28% at 10 years                   | 89% at 10 years   |   |

|                               | 10 years   |                        |           |  |                               |
|-------------------------------|--|------------------------|-----------|--|-------------------------------|
| Sensitivity to chemotherapy   | None   | None                   | Uncertain | Possibly, if high percentage round cells | None                          |
| Sensitivity to radiotherapy   | Low  | Low                    | Low       |  | Low                           |
| Potential targets for therapy | PTHLH (BCL2), IHH, PDGFR-a, COX-2, MMP, ER, HDAC | PTHLH (BCL2), ER, HDAC | None      | BCL2, c-PKC-a, PDGFR-a                   | PTHLH (BCL2), PDGF, MMP2, IHH |

\* Abbreviations: BCL2=*B-cell lymphoma 2 protein*; COX-2=*cyclooxygenase 2*; ER=*estrogen receptor*; HDAC=*histone deacetylase*; IHH=*Indian hedgehog*; MMP=*matrix metalloproteinase*; PDGFR-a=*platelet-derived growth factor receptor a*; PTHLH=*parathyroid hormone-like hormone*.

### *Treatment*

All 24 cases of pelvic chondrosarcoma underwent surgical treatment, including 15 cases of resection and reconstruction in the first operation, 8 cases of resection and no reconstruction, and 1 case of hip amputation (when the patient was found, the tumor was huge and invaded major blood vessels and important nerves, so limb salvage operation was not possible). 16 patients underwent 2 or more operations due to local recurrence or postoperative dysfunction, of which 12 were ended up with amputations. A total of 5 patients were treated with chemotherapy, including 1 preoperative chemotherapy and 4 postoperative chemotherapy. The chemotherapy regimen includes ifosfamide + doxorubicin + azolidazole, ifosfamide + doxorubicin, or methotrexate + epirubicin. 3 patients were treated with postoperative radiotherapy.

### *Follow-up*

The patient should be followed up to the clinic once every 3 months for the re-examination of the surgical site's X-ray and chest radiographs within 2 years of the surgery. Computed tomography (CT) or magnetic resonance imaging (MRI) should be performed if required. If there were no signs of progress, the follow-up was changed to once every six months after 2 years and once every year after 5 years. Follow-up records included local recurrence and distant metastasis. If the patient died, the time of death was confirmed by telephone follow-up. The duration of follow-up was defined as from the time of diagnosis until the patient died or was counted.

### *Statistical analysis*

IBM SPSS Statistics 24.0 software was used for data collection and statistical analysis. Pearson  $\chi^2$  test was used to test the correlation between the two categorical variables, and Fisher's exact

probability method was used if the frequency was <5. Kaplan-Meier method was used to analyze survival and estimate survival rate. COX regression model was used for univariate analysis of survival time. When these variables are incorporated into the COX regression model for multi-factor analysis, the independent variables are screened by the advanced method based on maximum likelihood estimation. P<0.05 indicated that the difference was statistically significant.

## Results

### *Clinical features of pelvic chondrosarcoma*

Chondrosarcomas of the pelvis were rarely classified as grade I, with only 1 in 24 (3.8%), compared to 26.5% in other chondrosarcomas. The local recurrence rate of pelvic chondrosarcoma was significantly higher than the other sites 83.3% (20 cases), but only 34.7% (17 cases). During treatment, the percentage of lesions located in the pelvis that eventually underwent amputation was significantly higher than in non-pelvic areas (50.0% in 12 cases). 3 patients (12.5%) with pelvic chondrosarcoma received postoperative radiotherapy, but no patients with tumors of other sites receiving radiotherapy. A total of 73 patients with chondrosarcoma were included in this study with a male to female ratio of 1.03:1, showing no significant gender bias. There was no statistically significant difference in the gender, age, chemotherapy or distant metastasis between pelvic chondrosarcoma patients and non-pelvic chondrosarcoma patients. (**Table 2, Figure 1**)

**Table 2-** Different characteristics between pelvic and non-pelvic chondrosarcomas:

| Factors            | Pelvis/n(%) | Other parts/n(%) | $\chi^2$ value | P-value |
|--------------------|-------------|------------------|----------------|---------|
| Gender             |             |                  | 0.837          | 0.360   |
| Female             | 10 (41.7)   | 26 (53.1)        |                |         |
| Male               | 14 (58.3)   | 23 (46.9)        |                |         |
| Age                |             |                  | 0.89           | 0.345   |
| < 50 years         | 16 (66.7)   | 27 (55.1)        |                |         |
| > 50 years         | 8 (33.3)    | 22 (44.9)        |                |         |
| Histological grade |             |                  | 5.307          | 0.070   |
| I grade            | 1(4.2)      | 13 (26.5)        |                |         |
| II grade           | 15 (62.5)   | 22 (44.9)        |                |         |
| III grade          | 8 (33.3)    | 14 (28.6)        |                |         |
| Amputation         |             |                  | 6.7            | 0.010   |
| Yes                | 12 (50.0)   | 10 (20.4)        |                |         |
| Not                | 12 (50.0)   | 39 (79.6)        |                |         |
| Chemotherapy       |             |                  | -              | 0.720 ① |
| Yes                | 4(16.7)     | 6(12.2)          |                |         |

|                  |     |           |            |       |         |
|------------------|-----|-----------|------------|-------|---------|
| Radiotherapy     | Not | 20 (83.3) | 43 (87.8)  | -     | 0.033 ① |
|                  | Yes | 3 (12.5)  | 0 (0.0)    |       |         |
| Local recurrence | Not | 21 (87.5) | 49 (100.0) | -     | 0.000 ① |
|                  | Yes | 20 (83.3) | 17 (34.7)  |       |         |
|                  | Not | 4(16.7)   | 32 (65.3)  |       |         |
| Metastasis       | Yes | 8 (33.3)  | 11 (22.4)  | 0.991 | 0.319   |
|                  | Not | 16 (66.7) | 38 (77.6)  |       |         |

Note: ①=Fisher's exact test.




Figure 1

### *Recurrence and metastasis of pelvic chondrosarcoma*


Diagnostic methods for local recurrence or distant metastasis include CT, MRI, isotope bone scan, PET-CT, and biopsy. In this study, the I area of patients is 5 cases, 2 underwent reconstruction with allograft bone graft, and all postoperatively recovered well; area II hip joint tumor and if do surgery then generally need to rebuild with restoring joint function. In this study, 9 of the 14 patients were constructed with artificial weight (saddle prosthesis or artificial acetabular cup), among 3 had a deep infection, and 2 had dislocation; There were no complications in 1 case of artificial bone grafting and 1 case of pelvic amputation. Only 3 cases were cleared without reconstruction, 1 of which was complicated with deep postoperative infection. The pelvic chondrosarcomas surgically removed, and at least 1 local recurrence occurred in 20 patients. Recurrence interval refers to the time from surgery to local recurrence (if any), ranging from 1.7 to 59.4 months, with a median time of 21.7 months. The survival of patients with pelvic chondrosarcoma without local recurrence was shorter than patients with other tumors ( $P=0.005$ ). The time interval between surgery and distant metastasis was 5.2 - 66.0 months, and the median time was 32.4 months. The distant metastases included 5 cases of lung, 1 case of the abdominal cavity, 1 case of retroperitoneum, and 1 case of multiple metastases of lung and abdominal cavity. In comparison, patients with high differentiation in other parts accounted for 26.5%, indicating that chondrosarcoma of the pelvis was more malignant. In this study, pelvic chondrosarcoma was the second most common site of the disease after the femur accounting for 32.9%, which is slightly higher than similar studies [7,12].

### *Prognostic analysis of pelvic chondrosarcoma*

The median follow-up time of 73 patients with chondrosarcoma was 60.1 months, with 21 deaths, 50 cases surviving, and 4 cases missing in the follow-up. The overall survival rates at 3, 5 and 10 years were  $(86.9\pm 4.1)\%$ ,  $(79.5\pm 5.2)\%$ , and  $(64.7\pm 6.9)\%$  respectively. The median follow-up time of 24 patients with pelvic chondrosarcoma was 67.4 months including 13 patients died, 11 surviving, and 2 missing in the follow-up. The 3, 5 and 10-year survival rates were  $(82.2\pm 8.1)\%$ ,  $(77.3\pm 8.9)\%$ , and  $(52.4\pm 12.1)\%$  respectively.


The total survival time of pelvic and non-pelvic chondrosarcoma patients was not significantly different ( $P=0.216$ ), as shown in **Figure 2**. The univariate analysis shows the overall survival time of patients with pelvic chondrosarcoma, including variables such as gender, age at diagnosis at <50 years, tumor's Enneking grade system, maximum diameter > 8 cm, histological grade, final

amputation, chemotherapy & radiotherapy whether or not, recurrence or not, and whether the time from surgery to recurrence within <1 year. The results showed a significantly shorter survival time for patients with local recurrence within 1 year ( $P = 0.001$ ), as shown in **Figure 3**. Further multivariate analysis indicated that local recurrence was the only independent prognostic factor within 1 year. Patients' gender, age, tumor site, size, histological grade, eventual amputation, chemotherapy or radiotherapy, and recurrence were not related to overall survival (**Table 3**).



**Figure 2**





**Figure 3**

**Table 3-** Univariate prognostic factors analysis of pelvic chondrosarcomas:

| Factors                   | n  | HR    | 95% CI         | P-value |
|---------------------------|----|-------|----------------|---------|
| Gender                    |    |       |                | 0.780   |
| Female                    | 10 | 1.185 | 0.360 ~ 3.899  |         |
| Male                      | 14 | -     |                |         |
| Age                       |    |       |                | 0.130   |
| < 50y ears                | 16 | 0.394 | 0.118 ~ 1.317  |         |
| > 50 years                | 8  | -     |                |         |
| Enneking system           |    |       |                | 0.379   |
| I area                    | 5  | 1.944 | 0.353 ~ 10.694 |         |
| II area                   | 14 | 0.767 | 0.148 ~ 3.972  |         |
| III area                  | 5  | -     |                |         |
| Maximum diameter of tumor |    |       |                | 0.280   |
| < 8 cm                    | 10 | 1.926 | 0.586 ~ 6.327  |         |

|                                      |    |        |                |       |
|--------------------------------------|----|--------|----------------|-------|
| > 8 cm                               | 14 | -      |                |       |
| Pathological grade                   |    |        |                | 0.759 |
| I grade                              | 1  | 0      | >0.000         |       |
| II grade                             | 15 | 0.637  | 0.194 ~ 2.093  |       |
| III grade                            | 8  | -      |                |       |
| Amputation                           |    |        |                | 0.963 |
| Yes                                  | 12 | 0.963  | 0.287 ~ 3.288  |       |
| Not                                  | 12 | -      |                |       |
| Chemotherapy                         |    |        |                | 0.297 |
| Yes                                  | 5  | 1.925  | 0.562 ~ 6.594  |       |
| Not                                  | 19 | -      |                |       |
| Radiotherapy                         |    |        |                | 0.764 |
| Yes                                  | 3  | 1.267  | 0.271 ~ 5.920  |       |
| Not                                  | 21 | -      |                |       |
| Local recurrence                     |    |        |                | 0.303 |
| yes                                  | 20 | 28.761 | 0.048 ~ 17.239 |       |
| Not                                  | 4  | -      |                |       |
| Time between surgery<br>& recurrence |    |        |                | 0.001 |
| < 1 years                            | 8  | 17.032 | 3.197 ~ 90.745 |       |
| > 1 years                            | 16 | -      |                |       |

## Discussion

The pelvic anatomical structure is complicated. Pelvic tumor surgery is difficult with high risk and many postoperative complications. This study analyzes and summarizes the clinical statistics and prognostic factors of pelvic and non-pelvic chondrosarcoma to provide a reference for the clinical diagnosis, treatment of the disease, and to improve the patient's life quality. The age range was 17 to 87 years, with a median age of 46 years, showing demographic characteristics similar to those of previous studies [7, 11-12]. Pelvic tumors were partitioned according to Enneking [10], and the largest proportion of tumors were in area II, reaching 58.3%; because they involve the hip joint, and it is undoubtedly increasing the difficulty of surgery. The size of the tumor varied depending on whether the tumor was located in the pelvis. The mean maximum diameter of the tumor in the pelvis was 10.5 cm, while that in other parts was 7.1 cm. There were also significant differences in tumor grades according to different sites. The histological manifestations of chondrosarcoma of the pelvis were very few (4.2%), and most of them were of medium and low differentiation.

Pelvic chondrosarcoma is not easy to be diagnosed and treated early. The main reason is that there is a large space in the pelvis for tumor growth, resulting in obvious swelling, compression, pain,

and other symptoms later. Chondrosarcoma should be highly suspected in cases of pelvic tumors, where a puncture or open biopsy indicates the origin of cartilage carefully identify. If it is confirmed as a benign tumor, then it should be followed up closely postoperatively and alert to secondary malignant changes. In this study, 2 cases (8.3%) were secondary chondrosarcomas of benign tumors. Surgical procedures for pelvic chondrosarcoma may be selected according to the Enneking subdivision. Attention should be paid to the operation because the sciatic nerve out of the outside of the pelvis often and has iliac vessels branch of the superior gluteal blood vessels through.

The surgeon mustn't avoid the first ligation of the blood vessels to avoid the occurrence of uncontrolled bleeding.

Adequate soft tissue coverage is the key to the success of the operation. Compared with traditional customized prosthesis 3D printing can achieve a satisfactory reconstruction effect; This kind of prosthesis has been routinely used in our hospital in recent years because of its good Angle matching in the acetabular cup and the difficulty of femoral head dislocation. If the tumor in area III does not involve the hip joint, only sitting and pubic resection will have less damage to the stability of the pelvis and do not affect the function of the hip joint. It can only be filled with a bone graft or rebuild. Since the sciatic tubercle is closer to the sciatic nerve, the sciatic nerve should be fully exposed and protected during surgery to avoid injury. In this study, 2 of the 5 patients underwent artificial hip reconstruction due to the involvement of the hip joint, of which 1 had deep postoperative infections; 2 had the only resection and 1 had no significant complications after amputation. Area IV is the metatarsal tumor, if total metatarsal resection is performed, reconstruction is required; Generally, a screw rod system is used to connect the spine and the metatarsal bone to maintain the stability of the pelvic ring [13]. This study did not include this type of case.

Non-surgical treatments for chondrosarcomas are limited and the efficacy of chemotherapy for chondrosarcoma remains controversial [3-5]. However, Kawaguchi et al. [6] showed that for dedifferentiated chondrosarcomas, surgical resection combined with ifosfamide chemotherapy resulted in significantly longer disease-free survival than patients treated with surgery alone. Italiano et al. [14] studied the response of advanced chondrosarcomas to chemotherapy (unretractable or with distant metastasis), showing that multi-drug combination chemotherapy can significantly delay the onset of disease progression, especially in patients with mesenchymal and

dedifferentiated chondrosarcomas. Some scholars have also explored targeted therapy for chondrosarcoma, focusing more on chemokine receptor 4 (CXCR4). This receptor can increase the expression of vascular endothelial growth factor (VEGF), induce angiogenesis and improve cell invasiveness [15]. Sun et al. [16] have successfully inhibited tumor growth and lung metastasis in a mouse chondrosarcoma transplantation model with its specific blocking drug AMD3100. Therefore, for mesenchymal and dedifferentiated chondrosarcomas, adjuvant chemotherapy can be used to control the progression of the disease if the tumor is characterized by rapid growth, blurred boundary, multiple postoperative recurrences and other features indicating a high degree of malignancy. Further research is needed to find more sensitive drugs to standardize adjuvant therapy. It is generally believed that chondrosarcoma is not sensitive to radiotherapy, and possible reasons include the deletion of tumor suppressor gene P16 in chondrosarcoma cells and increased expression of anti-apoptotic proteins such as Bcl-2, Bcl-xL and XIAP [17]. Previous clinical studies also mostly confirmed that radiotherapy could not improve the prognosis of chondrosarcoma [18-19]. However, a retrospective study of 31 cases of pelvic chondrosarcoma by Outani et al. [20] showed that carbon ion radiotherapy had no significant effect on the survival time of patients, and the limb function of the patients was significantly better than the surgery group.

A clinical trial by Uhl et al. [21] also showed that carbon-ion radiotherapy for middle and low-level cranial base chondrosarcoma could achieve better local control with fewer adverse reactions. carbocation radiotherapy is a trial-and-true treatment option for pelvic chondrosarcoma patients who are difficult to treat surgically and not sensitive to chemotherapy. In this study, 3 patients with pelvic chondrosarcoma were treated with radiotherapy, 2 of whom were treated with radiotherapy after amputation and had died at the time of follow-up. In this study, pelvic chondrosarcoma was more likely to recurrence with a local recurrence rate of 83.3% after surgical resection. Combined with the existing studies, it can be found that the local recurrence rate after resection varies greatly with different sites and operation methods. Roos et al. [22] reported a local recurrence rate of 17.1% within 5 years after primary rib chondrosarcoma resection. Al-Refaie et al. [23] reported a local recurrence rate of 4.4% after chest wall chondrosarcoma. Yin et al. [18] reported the local recurrence rate of chondrosarcoma after the operation was 42.9%. Ogose et al. [24] reported that the postoperative recurrence rate of hand and foot chondrosarcoma was 40.4%, and the recurrence rate was closely related to the surgical procedure. Tumor recurrence after amputation, lesion

resection and curettage the rates decreased in turn, which suggests that sufficient resection range can reduce the local recurrence rate.

In this study, it was found that recurrence did not affect the overall survival time of patients, but the prognosis of patients with earlier recurrence (<1 year) was poor, which was consistent with the existing research results [19]; which may be a manifestation of the high malignant degree of the tumor. In this study, the proportion of pelvic chondrosarcoma with metastasis was 33.3% and the sites were lung, abdominal cavity and retroperitoneal. Previous studies have also shown that chondrosarcomas are most likely to metastasize to the lungs [18, 25-26]. Compared with other chondrosarcomas, the proportion of spinal metastasis was 24.5% [18], 17.1% [24], and 11.8% [22]. The probability of pelvic metastasis is relatively high, which is consistent with previous research results suggesting that the overall malignant degree of pelvic chondrosarcoma is higher than other sites [8]. This study has some limitations and it may also have susceptible to bias associated with certain patients being reported over others, so further study should be conducted.

### **Conclusion**

The local recurrence rate after surgical resection of pelvic chondrosarcoma was significantly higher than other chondrosarcomas, and the final amputation rate was also significantly higher. Local recurrence within 1 year after surgery is an independent prognostic factor for pelvic chondrosarcoma. Some findings of this study are supported previously published literatures. Analysis of the difference between surgical techniques, clinical statistics, prognostic factors, and patient outcomes has been limited because of the rarity of these lesions and few institutions having enough patients to study about it.

### **Abbreviation**

None

### **Ethical approval**

The ethics committee approved this manuscript and design plan.

### **Statement of Informed Consent**

No consent was needed because the database is publicly available and does not include unique patient identifiers.

### **Availability of data and materials**

By reasonable request, the author will provide data.

### **Authors' contributions**

SAJ & SJ conceived and designed the study; SAJ, BSR, LCH, and ZZ collected the data; SAJ, BSR & LCH checked the follow-up; SAJ, ZZ & BSR wrote different parts of the manuscript; SJ revised the manuscript.

## **Funding**

None

## **Interests of competing**

None of the authors have competing interests.

## **References**

1. Giuffrida AY, Burgueno JE, Koniaris LG, Gutierrez JC, Duncan R, Scully SP. Chondrosarcoma in the United States (1973 to 2003): an analysis of 2890 cases from the SEER database. *JBJS*. 2009;91(5):1063-72.
2. Krol AD, Taminiau AH, Bovée JV. The clinical approach towards chondrosarcoma. *The oncologist*. 2008;13:320-9.
3. Staals EL, Bacchini P, Bertoni F. Dedifferentiated central chondrosarcoma. *Cancer: Interdisciplinary International Journal of the American Cancer Society*. 2006;106(12):2682-91.
4. Dickey ID, Rose PS, Fuchs B, Wold LE, Okuno SH, Sim FH, et al. Dedifferentiated chondrosarcoma: the role of chemotherapy with updated outcomes. *JBJS*. 2004;86(11):2412-8.
5. Grimer RJ, Gosheger G, Taminiau A, Biau D, Matejovsky Z, Kollender Y, et al. Dedifferentiated chondrosarcoma: prognostic factors and outcome from a European group. *European journal of cancer*. 2007;43(14):2060-5.
6. Kawaguchi S, Sun T, Lin PP, Deavers M, Harun N, Lewis VO. Does ifosfamide therapy improve survival of patients with dedifferentiated chondrosarcoma? *Clinical Orthopaedics and Related Research*®. 2014;472(3):983-9.
7. Angelini A, Guerra G, Mavrogenis AF, Pala E, Picci P, Ruggieri P. Clinical outcome of central conventional chondrosarcoma. *Journal of surgical oncology*. 2012;106(8):929-37.
8. Lee FY, Mankin HJ, Fondren G, Gebhardt MC, Springfield DS, Rosenberg AE, et al. chondrosarcoma of bone: an assessment of outcome. *JBJS*. 1999;81(3):326-38.
9. Zeifang F, Buchner M, Zahlten-Hinguranage A, Bernd L, Sabo D. Complications following operative treatment of primary malignant bone tumours in the pelvis. *European Journal of Surgical Oncology (EJSO)*. 2004;30(8):893-9.
10. Enneking WF, Dunham W. Resection and reconstruction for primary neoplasms involving the innominate bone. *The Journal of bone and joint surgery American volume*. 1978;60(6):731-46.
11. Bindiganavile S, Han I, Yun JY, Kim H-S. Long-term outcome of chondrosarcoma: a single institutional experience. *Cancer research and treatment: official journal of Korean Cancer Association*. 2015;47(4):897.
12. Konishi E, Nakashima Y, Mano M, Tomita Y, Nagasaki I, Kubo T, et al. Primary central chondrosarcoma of long bone, limb girdle and trunk: Analysis of 174 cases by numerical scoring on histology. *Pathology international*. 2015;65(9):468-75.
13. Bederman SS, Shah KN, Hassan JM, Hoang BH, Kiester PD, Bhatia NN. Surgical techniques for spinopelvic reconstruction following total sacrectomy: a systematic review. *European Spine Journal*. 2014;23(2):305-19.
14. Italiano A, Mir O, Cioffi A, Palmerini E, Piperno-Neumann S, Perrin C, et al. Advanced chondrosarcomas: role of chemotherapy and survival. *Annals of oncology*. 2013;24(11):2916-22.

15. Liang Z, Brooks J, Willard M, Liang K, Yoon Y, Kang S, et al. CXCR4/CXCL12 axis promotes VEGF-mediated tumor angiogenesis through Akt signaling pathway. *Biochemical and biophysical research communications*. 2007;359(3):716-22.
16. Sun X, Charbonneau C, Wei L, Yang W, Chen Q, Terek RM. CXCR4-targeted therapy inhibits VEGF expression and chondrosarcoma angiogenesis and metastasis. *Molecular cancer therapeutics*. 2013;12(7):1163-70.
17. Onishi AC, Hincker AM, Lee FY. Surmounting chemotherapy and radioresistance in chondrosarcoma: molecular mechanisms and therapeutic targets. *Sarcoma*. 2010;2011.
18. Yin H, Zhou W, Meng J, Zhang D, Wu Z, Wang T, et al. Prognostic factors of patients with spinal chondrosarcoma: a retrospective analysis of 98 consecutive patients in a single center. *Annals of surgical oncology*. 2014;21(11):3572-8.
19. Kim HS, Bindiganavile SS, Han I. Oncologic outcome after local recurrence of chondrosarcoma: analysis of prognostic factors. *Journal of surgical oncology*. 2015;111(8):957-61.
20. Outani H, Hamada K, Imura Y, Oshima K, Sotobori T, Demizu Y, et al. Comparison of clinical and functional outcome between surgical treatment and carbon ion radiotherapy for pelvic chondrosarcoma. *International journal of clinical oncology*. 2016;21(1):186-93.
21. Uhl M, Mattke M, Welzel T, Oelmann J, Habl G, Jensen AD, et al. High control rate in patients with chondrosarcoma of the skull base after carbon ion therapy: first report of long-term results. *Cancer*. 2014;120(10):1579-85.
22. Roos E, van Coevorden F, Verhoef C, Wouters MW, Kroon HM, Hogendoorn PC, et al. Prognosis of primary and recurrent chondrosarcoma of the rib. *Annals of surgical oncology*. 2016;23(3):811-7.
23. Al-Refaie RE, Amer S, Ismail MF, Al-Shabrawy M, Al-Gamal G, Mokbel E. Chondrosarcoma of the chest wall: single-center experience. *Asian Cardiovascular and Thoracic Annals*. 2014;22(7):829-34.
24. Ogose A, Unni KK, Swee RG, May GK, Rowland CM, Sim FH. Chondrosarcoma of small bones of the hands and feet. *Cancer: Interdisciplinary International Journal of the American Cancer Society*. 1997;80(1):50-9.
25. Widhe B, Bauer HC. Surgical treatment is decisive for outcome in chondrosarcoma of the chest wall: a population-based Scandinavian Sarcoma Group study of 106 patients. *The Journal of thoracic and cardiovascular surgery*. 2009;137(3):610-4.
26. Strotman PK, Reif TJ, Kliethermes SA, Sandhu JK, Nystrom LM. Dedifferentiated chondrosarcoma: a survival analysis of 159 cases from the SEER database (2001-2011). *Journal of surgical oncology*. 2017;116(2):252-7.